Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 16 entries
Sorted by: Best Match Show Resources per page
Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

CPT: pharmacometrics & systems pharmacology

van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD.
PMID: 26312162
CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):386-95. doi: 10.1002/psp4.49. Epub 2015 Jun 30.

Frameworks that associate cancer dynamic disease progression models with parametric survival models for clinical outcome have recently been proposed to support decision making in early clinical development. Here we developed such a disease progression clinical outcome model for castration-resistant...

Cite
van Hasselt JG, Gupta A, Hussein Z, et al. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. CPT Pharmacometrics Syst Pharmacol. 2015;4(7):386-95doi: 10.1002/psp4.49.
van Hasselt, J. G., Gupta, A., Hussein, Z., Beijnen, J. H., Schellens, J. H., & Huitema, A. D. (2015). Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. CPT: pharmacometrics & systems pharmacology, 4(7), 386-95. https://doi.org/10.1002/psp4.49
van Hasselt, J G C, et al. "Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin." CPT: pharmacometrics & systems pharmacology vol. 4,7 (2015): 386-95. doi: https://doi.org/10.1002/psp4.49
van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD. Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin. CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):386-95. doi: 10.1002/psp4.49. Epub 2015 Jun 30. PMID: 26312162; PMCID: PMC4544052.
Copy Download .nbib Format: NLM
Rheumatic diseases of the nervous system.

Nederlands tijdschrift voor geneeskunde

VAN HASSELT JA.
PMID: 18902973
Ned Tijdschr Geneeskd. 1948 Jan 03;92(1):67-9.

No abstract available.

Cite
VAN HASSELT JA. Rheumatische aandoeningen van het zenuwstelsel. Rheumatic diseases of the nervous system. Ned Tijdschr Geneeskd. 1948;92(1):67-9
VAN HASSELT, J. A. (1948). Rheumatische aandoeningen van het zenuwstelsel. Rheumatic diseases of the nervous system. Nederlands tijdschrift voor geneeskunde, 92(1), 67-9.
VAN HASSELT, J A. "Rheumatische aandoeningen van het zenuwstelsel." Rheumatic diseases of the nervous system. Nederlands tijdschrift voor geneeskunde vol. 92,1 (1948): 67-9.
VAN HASSELT JA. Rheumatische aandoeningen van het zenuwstelsel. Rheumatic diseases of the nervous system. Ned Tijdschr Geneeskd. 1948 Jan 03;92(1):67-9. Dutch. PMID: 18902973.
Copy Download .nbib Format: NLM
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.

Trends in pharmacological sciences

Mehta K, Spaink HP, Ottenhoff THM, van der Graaf PH, van Hasselt JGC.
PMID: 34916092
Trends Pharmacol Sci. 2021 Dec 13; doi: 10.1016/j.tips.2021.11.016. Epub 2021 Dec 13.

Host-directed therapies (HDTs) that modulate host-pathogen interactions offer an innovative strategy to combat Mycobacterium tuberculosis (Mtb) infections. When combined with tuberculosis (TB) antibiotics, HDTs could contribute to improving treatment outcomes, reducing treatment duration, and preventing resistance development. Translation of...

Cite
Mehta K, Spaink HP, Ottenhoff THM, et al. Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches. Trends Pharmacol Sci. 2021;doi: 10.1016/j.tips.2021.11.016.
Mehta, K., Spaink, H. P., Ottenhoff, T. H. M., van der Graaf, P. H., & van Hasselt, J. G. C. (2021). Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches. Trends in pharmacological sciences, . https://doi.org/10.1016/j.tips.2021.11.016
Mehta, Krina, et al. "Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches." Trends in pharmacological sciences vol. (2021). doi: https://doi.org/10.1016/j.tips.2021.11.016
Mehta K, Spaink HP, Ottenhoff THM, van der Graaf PH, van Hasselt JGC. Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches. Trends Pharmacol Sci. 2021 Dec 13; doi: 10.1016/j.tips.2021.11.016. Epub 2021 Dec 13. PMID: 34916092.
Copy Download .nbib Format: NLM
Identification of antibiotic collateral sensitivity and resistance interactions in population surveillance data.

JAC-antimicrobial resistance

Zwep LB, Haakman Y, Duisters KLW, Meulman JJ, Liakopoulos A, van Hasselt JGC.
PMID: 34859221
JAC Antimicrob Resist. 2021 Nov 28;3(4):dlab175. doi: 10.1093/jacamr/dlab175. eCollection 2021 Dec.

BACKGROUND: Collateral effects of antibiotic resistance occur when resistance to one antibiotic agent leads to increased resistance or increased sensitivity to a second agent, known respectively as collateral resistance (CR) and collateral sensitivity (CS). Collateral effects are relevant to...

Cite
Zwep LB, Haakman Y, Duisters KLW, et al. Identification of antibiotic collateral sensitivity and resistance interactions in population surveillance data. JAC Antimicrob Resist. 2021;3(4):dlab175doi: 10.1093/jacamr/dlab175.
Zwep, L. B., Haakman, Y., Duisters, K. L. W., Meulman, J. J., Liakopoulos, A., & van Hasselt, J. G. C. (2021). Identification of antibiotic collateral sensitivity and resistance interactions in population surveillance data. JAC-antimicrobial resistance, 3(4), dlab175. https://doi.org/10.1093/jacamr/dlab175
Zwep, Laura B, et al. "Identification of antibiotic collateral sensitivity and resistance interactions in population surveillance data." JAC-antimicrobial resistance vol. 3,4 (2021): dlab175. doi: https://doi.org/10.1093/jacamr/dlab175
Zwep LB, Haakman Y, Duisters KLW, Meulman JJ, Liakopoulos A, van Hasselt JGC. Identification of antibiotic collateral sensitivity and resistance interactions in population surveillance data. JAC Antimicrob Resist. 2021 Nov 28;3(4):dlab175. doi: 10.1093/jacamr/dlab175. eCollection 2021 Dec. PMID: 34859221; PMCID: PMC8633787.
Copy Download .nbib Format: NLM
Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Poppe M, Clodi C, Schriefl C, Mueller M, Sunder-Plaßmann R, Reiter B, Rechenmacher M, van Os W, van Hasselt JGC, Holzer M, Herkner H, Schwameis M, Jilma B, Schoergenhofer C, Weiser C.
PMID: 34959115
Biomed Pharmacother. 2021 Dec 24;146:112573. doi: 10.1016/j.biopha.2021.112573. Epub 2021 Dec 24.

OBJECTIVE: Targeted temperature management (TTM) is part of standard post-resuscitation care. TTM may downregulate cytochrome enzyme activity and thus impact drug metabolism. This study compared the pharmacokinetics (PK) of pantoprazole, a probe drug of CYP2C19-dependent metabolism, at different stages...

Cite
Poppe M, Clodi C, Schriefl C, et al. Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism. Biomed Pharmacother. 2021;146:112573doi: 10.1016/j.biopha.2021.112573.
Poppe, M., Clodi, C., Schriefl, C., Mueller, M., Sunder-Plaßmann, R., Reiter, B., Rechenmacher, M., van Os, W., van Hasselt, J. G. C., Holzer, M., Herkner, H., Schwameis, M., Jilma, B., Schoergenhofer, C., & Weiser, C. (2021). Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112573. https://doi.org/10.1016/j.biopha.2021.112573
Poppe, Michael, et al. "Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112573. doi: https://doi.org/10.1016/j.biopha.2021.112573
Poppe M, Clodi C, Schriefl C, Mueller M, Sunder-Plaßmann R, Reiter B, Rechenmacher M, van Os W, van Hasselt JGC, Holzer M, Herkner H, Schwameis M, Jilma B, Schoergenhofer C, Weiser C. Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism. Biomed Pharmacother. 2021 Dec 24;146:112573. doi: 10.1016/j.biopha.2021.112573. Epub 2021 Dec 24. PMID: 34959115.
Copy Download .nbib Format: NLM
Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Poppe M, Clodi C, Schriefl C, Mueller M, Sunder-Plaßmann R, Reiter B, Rechenmacher M, van Os W, van Hasselt JGC, Holzer M, Herkner H, Schwameis M, Jilma B, Schoergenhofer C, Weiser C.
PMID: 34959115
Biomed Pharmacother. 2021 Dec 24;146:112573. doi: 10.1016/j.biopha.2021.112573. Epub 2021 Dec 24.

OBJECTIVE: Targeted temperature management (TTM) is part of standard post-resuscitation care. TTM may downregulate cytochrome enzyme activity and thus impact drug metabolism. This study compared the pharmacokinetics (PK) of pantoprazole, a probe drug of CYP2C19-dependent metabolism, at different stages...

Cite
Poppe M, Clodi C, Schriefl C, et al. Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism. Biomed Pharmacother. 2021;146:112573doi: 10.1016/j.biopha.2021.112573.
Poppe, M., Clodi, C., Schriefl, C., Mueller, M., Sunder-Plaßmann, R., Reiter, B., Rechenmacher, M., van Os, W., van Hasselt, J. G. C., Holzer, M., Herkner, H., Schwameis, M., Jilma, B., Schoergenhofer, C., & Weiser, C. (2021). Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 146112573. https://doi.org/10.1016/j.biopha.2021.112573
Poppe, Michael, et al. "Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie vol. 146 (2021): 112573. doi: https://doi.org/10.1016/j.biopha.2021.112573
Poppe M, Clodi C, Schriefl C, Mueller M, Sunder-Plaßmann R, Reiter B, Rechenmacher M, van Os W, van Hasselt JGC, Holzer M, Herkner H, Schwameis M, Jilma B, Schoergenhofer C, Weiser C. Targeted temperature management after cardiac arrest is associated with reduced metabolism of pantoprazole - A probe drug of CYP2C19 metabolism. Biomed Pharmacother. 2021 Dec 24;146:112573. doi: 10.1016/j.biopha.2021.112573. Epub 2021 Dec 24. PMID: 34959115.
Copy Download .nbib Format: NLM
Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS).

The Lancet. Infectious diseases

Thomson KM, Dyer C, Liu F, Sands K, Portal E, Carvalho MJ, Barrell M, Boostrom I, Dunachie S, Farzana R, Ferreira A, Frayne F, Hassan B, Jones E, Jones L, Mathias J, Milton R, Rees J, Chan GJ, Bekele D, Mahlet A, Basu S, Nandy RK, Saha B, Iregbu K, Modibbo F, Uwaezuoke S, Zahra R, Shirazi H, Syed NU, Mazarati JB, Rucogoza A, Gaju L, Mehtar S, Bulabula ANH, Whitelaw A, van Hasselt JGC, Walsh TR.
PMID: 34384533
Lancet Infect Dis. 2021 Dec;21(12):1677-1688. doi: 10.1016/S1473-3099(21)00050-5. Epub 2021 Aug 09.

BACKGROUND: Sepsis is a major contributor to neonatal mortality, particularly in low-income and middle-income countries (LMICs). WHO advocates ampicillin-gentamicin as first-line therapy for the management of neonatal sepsis. In the BARNARDS observational cohort study of neonatal sepsis and antimicrobial...

Cite
Thomson KM, Dyer C, Liu F, et al. Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). Lancet Infect Dis. 2021;21(12):1677-1688doi: 10.1016/S1473-3099(21)00050-5.
Thomson, K. M., Dyer, C., Liu, F., Sands, K., Portal, E., Carvalho, M. J., Barrell, M., Boostrom, I., Dunachie, S., Farzana, R., Ferreira, A., Frayne, F., Hassan, B., Jones, E., Jones, L., Mathias, J., Milton, R., Rees, J., Chan, G. J., Bekele, D., Mahlet, A., Basu, S., Nandy, R. K., Saha, B., Iregbu, K., Modibbo, F., Uwaezuoke, S., Zahra, R., Shirazi, H., Syed, N. U., Mazarati, J. B., Rucogoza, A., Gaju, L., Mehtar, S., Bulabula, A. N. H., Whitelaw, A., van Hasselt, J. G. C., Walsh, T. R. (2021). Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). The Lancet. Infectious diseases, 21(12), 1677-1688. https://doi.org/10.1016/S1473-3099(21)00050-5
Thomson, Kathryn M, et al. "Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS)." The Lancet. Infectious diseases vol. 21,12 (2021): 1677-1688. doi: https://doi.org/10.1016/S1473-3099(21)00050-5
Thomson KM, Dyer C, Liu F, Sands K, Portal E, Carvalho MJ, Barrell M, Boostrom I, Dunachie S, Farzana R, Ferreira A, Frayne F, Hassan B, Jones E, Jones L, Mathias J, Milton R, Rees J, Chan GJ, Bekele D, Mahlet A, Basu S, Nandy RK, Saha B, Iregbu K, Modibbo F, Uwaezuoke S, Zahra R, Shirazi H, Syed NU, Mazarati JB, Rucogoza A, Gaju L, Mehtar S, Bulabula ANH, Whitelaw A, van Hasselt JGC, Walsh TR. Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). Lancet Infect Dis. 2021 Dec;21(12):1677-1688. doi: 10.1016/S1473-3099(21)00050-5. Epub 2021 Aug 09. PMID: 34384533; PMCID: PMC8612937.
Copy Download .nbib Format: NLM
Protein structure-based gene expression signatures.

Proceedings of the National Academy of Sciences of the United States of America

Rahman R, Zatorski N, Hansen J, Xiong Y, van Hasselt JGC, Sobie EA, Birtwistle MR, Azeloglu EU, Iyengar R, Schlessinger A.
PMID: 33941686
Proc Natl Acad Sci U S A. 2021 May 11;118(19). doi: 10.1073/pnas.2014866118.

Gene expression signatures (GES) connect phenotypes to differential messenger RNA (mRNA) expression of genes, providing a powerful approach to define cellular identity, function, and the effects of perturbations. The use of GES has suffered from vague assessment criteria and...

Cite
Rahman R, Zatorski N, Hansen J, et al. Protein structure-based gene expression signatures. Proc Natl Acad Sci U S A. 2021;118(19)doi: 10.1073/pnas.2014866118.
Rahman, R., Zatorski, N., Hansen, J., Xiong, Y., van Hasselt, J. G. C., Sobie, E. A., Birtwistle, M. R., Azeloglu, E. U., Iyengar, R., & Schlessinger, A. (2021). Protein structure-based gene expression signatures. Proceedings of the National Academy of Sciences of the United States of America, 118(19), . https://doi.org/10.1073/pnas.2014866118
Rahman, Rayees, et al. "Protein structure-based gene expression signatures." Proceedings of the National Academy of Sciences of the United States of America vol. 118,19 (2021). doi: https://doi.org/10.1073/pnas.2014866118
Rahman R, Zatorski N, Hansen J, Xiong Y, van Hasselt JGC, Sobie EA, Birtwistle MR, Azeloglu EU, Iyengar R, Schlessinger A. Protein structure-based gene expression signatures. Proc Natl Acad Sci U S A. 2021 May 11;118(19). doi: 10.1073/pnas.2014866118. PMID: 33941686; PMCID: PMC8126868.
Copy Download .nbib Format: NLM
Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS).

The Lancet. Infectious diseases

Thomson KM, Dyer C, Liu F, Sands K, Portal E, Carvalho MJ, Barrell M, Boostrom I, Dunachie S, Farzana R, Ferreira A, Frayne F, Hassan B, Jones E, Jones L, Mathias J, Milton R, Rees J, Chan GJ, Bekele D, Mahlet A, Basu S, Nandy RK, Saha B, Iregbu K, Modibbo F, Uwaezuoke S, Zahra R, Shirazi H, Syed NU, Mazarati JB, Rucogoza A, Gaju L, Mehtar S, Bulabula ANH, Whitelaw A, van Hasselt JGC, Walsh TR.
PMID: 34384533
Lancet Infect Dis. 2021 Dec;21(12):1677-1688. doi: 10.1016/S1473-3099(21)00050-5. Epub 2021 Aug 09.

BACKGROUND: Sepsis is a major contributor to neonatal mortality, particularly in low-income and middle-income countries (LMICs). WHO advocates ampicillin-gentamicin as first-line therapy for the management of neonatal sepsis. In the BARNARDS observational cohort study of neonatal sepsis and antimicrobial...

Cite
Thomson KM, Dyer C, Liu F, et al. Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). Lancet Infect Dis. 2021;21(12):1677-1688doi: 10.1016/S1473-3099(21)00050-5.
Thomson, K. M., Dyer, C., Liu, F., Sands, K., Portal, E., Carvalho, M. J., Barrell, M., Boostrom, I., Dunachie, S., Farzana, R., Ferreira, A., Frayne, F., Hassan, B., Jones, E., Jones, L., Mathias, J., Milton, R., Rees, J., Chan, G. J., Bekele, D., Mahlet, A., Basu, S., Nandy, R. K., Saha, B., Iregbu, K., Modibbo, F., Uwaezuoke, S., Zahra, R., Shirazi, H., Syed, N. U., Mazarati, J. B., Rucogoza, A., Gaju, L., Mehtar, S., Bulabula, A. N. H., Whitelaw, A., van Hasselt, J. G. C., Walsh, T. R. (2021). Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). The Lancet. Infectious diseases, 21(12), 1677-1688. https://doi.org/10.1016/S1473-3099(21)00050-5
Thomson, Kathryn M, et al. "Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS)." The Lancet. Infectious diseases vol. 21,12 (2021): 1677-1688. doi: https://doi.org/10.1016/S1473-3099(21)00050-5
Thomson KM, Dyer C, Liu F, Sands K, Portal E, Carvalho MJ, Barrell M, Boostrom I, Dunachie S, Farzana R, Ferreira A, Frayne F, Hassan B, Jones E, Jones L, Mathias J, Milton R, Rees J, Chan GJ, Bekele D, Mahlet A, Basu S, Nandy RK, Saha B, Iregbu K, Modibbo F, Uwaezuoke S, Zahra R, Shirazi H, Syed NU, Mazarati JB, Rucogoza A, Gaju L, Mehtar S, Bulabula ANH, Whitelaw A, van Hasselt JGC, Walsh TR. Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS). Lancet Infect Dis. 2021 Dec;21(12):1677-1688. doi: 10.1016/S1473-3099(21)00050-5. Epub 2021 Aug 09. PMID: 34384533; PMCID: PMC8612937.
Copy Download .nbib Format: NLM
Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling.

CPT: pharmacometrics & systems pharmacology

Zwep LB, Duisters KLW, Jansen M, Guo T, Meulman JJ, Upadhyay PJ, van Hasselt JGC.
PMID: 33792207
CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):350-361. doi: 10.1002/psp4.12603. Epub 2021 Apr 08.

Pharmacometric modeling can capture tumor growth inhibition (TGI) dynamics and variability. These approaches do not usually consider covariates in high-dimensional settings, whereas high-dimensional molecular profiling technologies ("omics") are being increasingly considered for prediction of anticancer drug treatment response. Machine...

Cite
Zwep LB, Duisters KLW, Jansen M, et al. Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling. CPT Pharmacometrics Syst Pharmacol. 2021;10(4):350-361doi: 10.1002/psp4.12603.
Zwep, L. B., Duisters, K. L. W., Jansen, M., Guo, T., Meulman, J. J., Upadhyay, P. J., & van Hasselt, J. G. C. (2021). Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling. CPT: pharmacometrics & systems pharmacology, 10(4), 350-361. https://doi.org/10.1002/psp4.12603
Zwep, Laura B, et al. "Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling." CPT: pharmacometrics & systems pharmacology vol. 10,4 (2021): 350-361. doi: https://doi.org/10.1002/psp4.12603
Zwep LB, Duisters KLW, Jansen M, Guo T, Meulman JJ, Upadhyay PJ, van Hasselt JGC. Identification of high-dimensional omics-derived predictors for tumor growth dynamics using machine learning and pharmacometric modeling. CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):350-361. doi: 10.1002/psp4.12603. Epub 2021 Apr 08. PMID: 33792207; PMCID: PMC8099445.
Copy Download .nbib Format: NLM
Evidence-based drug treatment for special patient populations through model-based approaches.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ.
PMID: 28502674
Eur J Pharm Sci. 2017 Nov 15;109:S22-S26. doi: 10.1016/j.ejps.2017.05.022. Epub 2017 May 11.

The majority of marketed drugs remain understudied in some patient populations such as pregnant women, paediatrics, the obese, the critically-ill, and the elderly. As a consequence, currently used dosing regimens may not assure optimal efficacy or minimal toxicity in...

Cite
Krekels EHJ, van Hasselt JGC, van den Anker JN, et al. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017;109:S22-S26doi: 10.1016/j.ejps.2017.05.022.
Krekels, E. H. J., van Hasselt, J. G. C., van den Anker, J. N., Allegaert, K., Tibboel, D., & Knibbe, C. A. J. (2017). Evidence-based drug treatment for special patient populations through model-based approaches. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 109S22-S26. https://doi.org/10.1016/j.ejps.2017.05.022
Krekels, Elke H J, et al. "Evidence-based drug treatment for special patient populations through model-based approaches." European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences vol. 109 (2017): S22-S26. doi: https://doi.org/10.1016/j.ejps.2017.05.022
Krekels EHJ, van Hasselt JGC, van den Anker JN, Allegaert K, Tibboel D, Knibbe CAJ. Evidence-based drug treatment for special patient populations through model-based approaches. Eur J Pharm Sci. 2017 Nov 15;109:S22-S26. doi: 10.1016/j.ejps.2017.05.022. Epub 2017 May 11. PMID: 28502674.
Copy Download .nbib Format: NLM
Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin.

CPT: pharmacometrics & systems pharmacology

van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD.
PMID: 26312161
CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):374-85. doi: 10.1002/psp4.48. Epub 2015 Jun 30.

Quantitative model-based analyses are helpful to support decision-making in drug development. In oncology, disease progression/clinical outcome (DPCO) models have been used for early predictions of clinical outcome, but most of such approaches did not include adverse events or dose...

Cite
van Hasselt JG, Gupta A, Hussein Z, et al. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. CPT Pharmacometrics Syst Pharmacol. 2015;4(7):374-85doi: 10.1002/psp4.48.
van Hasselt, J. G., Gupta, A., Hussein, Z., Beijnen, J. H., Schellens, J. H., & Huitema, A. D. (2015). Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. CPT: pharmacometrics & systems pharmacology, 4(7), 374-85. https://doi.org/10.1002/psp4.48
van Hasselt, J G C, et al. "Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin." CPT: pharmacometrics & systems pharmacology vol. 4,7 (2015): 374-85. doi: https://doi.org/10.1002/psp4.48
van Hasselt JG, Gupta A, Hussein Z, Beijnen JH, Schellens JH, Huitema AD. Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin. CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):374-85. doi: 10.1002/psp4.48. Epub 2015 Jun 30. PMID: 26312161; PMCID: PMC4544051.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 16 entries